AVEED®LONG-ACTING testosterone injection for hypogonadal males1
  • AVEED® - LONG-ACTING testosterone injection for hypogonadal males1

    ELEVATE AND CONTROL TESTOSTERONE LEVELS WITH 5 SHOTS A YEAR AFTER THE FIRST MONTH OF THERAPY During the third dosing interval, 94% of men maintained testosterone levels within normal range; 5.1% of patients

    Review the Data
  • 94% OF MEN MAINTAINED NORMAL LEVELS FOR THE FULL 10 WEEKS DURING THE THIRD DOSING INTERVAL

    Over the full 10 weeks at steady state: 5.1% of patients

    Explore Efficacy
  • Become an AVEED® Prescriber

    Only enrolled and certified healthcare professionals can prescribe AVEED®. To become an AVEED® prescriber, please register for, and complete, the AVEED® REMS* Program.

    Enroll Now
  • Get Listed on the AVEEDfinder and Make it Easy for Patients to Find You

    With the AVEEDfinder tool, patients can locate a healthcare professional certified to prescribe AVEED® based on zip code, physician name, or practice name.

    Get Listed Now

Get Listed on
AVEEDfinder

Sign up with AVEEDfinder so patients can search for you.

Sign Up

Patient Savings

Depending on your patients' insurance, and other relevant factors, they may be eligible for savings.

Learn About Savings
for Your Patients

Become
a Prescriber

Learn how you can become a prescriber through the AVEED® REMS* Program.

How Can You
Become a Prescriber?
*Risk Evaluation and Mitigation Strategy.
INDICATIONS AND USAGE

AVEED® (testosterone undecanoate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.

Limitations of use:
  • Safety and efficacy of AVEED® in men with "age-related hypogonadism" have not been established.
  • Safety and efficacy of AVEED® in males less than 18 years old have not been established.
SELECTED SAFETY INFORMATION about AVEED®

WARNING: SERIOUS PULMONARY OIL MICROEMBOLISM (POME) REACTIONS AND ANAPHYLAXIS

  • Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.
  • Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.
  • Because of the risks of serious POME reactions and anaphylaxis, AVEED® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AVEED® REMS Program.

CONTRAINDICATIONS

  • Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Women who are or may become pregnant, or who are breastfeeding. Testosterone can cause fetal harm when administered to a pregnant woman. AVEED® may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization.
  • Men with known hypersensitivity to AVEED® or any of its ingredients (testosterone undecanoate, refined castor oil, benzyl benzoate).

WARNINGS AND PRECAUTIONS

  • Serious Pulmonary Oil Microembolism (POME) Reactions and Anaphylaxis

    Serious POME reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL). The majority of these events lasted a few minutes and resolved with supportive measures; however, some lasted up to several hours and some required emergency care and/or hospitalization. To minimize the risk of intravascular injection of AVEED®, care should be taken to inject the preparation deeply into the gluteal muscle, being sure to follow the recommended procedure for intramuscular administration.

    In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate.

    Both serious POME reactions and anaphylaxis can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose. Patients with suspected hypersensitivity reactions to AVEED® should not be re-treated with AVEED®.

    Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions and anaphylaxis.

More Safety Info
 
INDICATIONS AND USAGE

AVEED® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.

Limitations of use:
  • Safety and efficacy of AVEED® in men with "age-related hypogonadism" have not been established.
  • Safety and efficacy of AVEED® in males less than 18 years old have not been established.
IMPORTANT SAFETY INFORMATION about AVEED®

WARNING: SERIOUS PULMONARY OIL MICROEMBOLISM (POME) REACTIONS AND ANAPHYLAXIS

  • Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.
  • Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.
  • Because of the risks of serious POME reactions and anaphylaxis, AVEED® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AVEED® REMS Program.

CONTRAINDICATIONS

  • Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Women who are or may become pregnant, or who are breastfeeding. Testosterone can cause fetal harm when administered to a pregnant woman. AVEED® may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization.
  • Men with known hypersensitivity to AVEED® or any of its ingredients (testosterone undecanoate, refined castor oil, benzyl benzoate).

WARNINGS AND PRECAUTIONS

  • Serious Pulmonary Oil Microembolism (POME) Reactions and Anaphylaxis

    Serious POME reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL). The majority of these events lasted a few minutes and resolved with supportive measures; however, some lasted up to several hours and some required emergency care and/or hospitalization. To minimize the risk of intravascular injection of AVEED®, care should be taken to inject the preparation deeply into the gluteal muscle, being sure to follow the recommended procedure for intramuscular administration.

    In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate.

    Both serious POME reactions and anaphylaxis can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose. Patients with suspected hypersensitivity reactions to AVEED® should not be re-treated with AVEED®.

    Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions and anaphylaxis.

  • AVEED® Risk Evaluation and Mitigation Strategy (REMS) Program

    AVEED® is available only through a restricted program called the AVEED® REMS Program because of the risk of serious POME and anaphylaxis.

    Notable requirements of the AVEED® REMS Program include the following:

    • Healthcare providers who prescribe AVEED® must be certified with the REMS Program before ordering or dispensing AVEED®.
    • Healthcare settings must be certified with the REMS Program and have healthcare providers who are certified before ordering or dispensing AVEED®. Healthcare settings must have on-site access to equipment and personnel trained to manage serious POME and anaphylaxis.

    Further information is available at www.AveedREMS.com or call 1-855-755-0494.

  • Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer - Patients with BPH treated with androgens are at an increased risk of worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at an increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens.
  • Polycythemia - Increases in hematocrit, reflective of increases in red blood cell mass, may require discontinuation of testosterone. Check hematocrit prior to initiating testosterone treatment. It would be appropriate to re-evaluate the hematocrit 3 to 6 months after starting testosterone treatment, and then annually. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable level. An increase in red blood cell mass may increase the risk of thromboembolic events.
  • Venous thromboembolism (VTE) - There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as AVEED®. Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with AVEED® and initiate appropriate workup and management.
  • Cardiovascular Risk - Some postmarketing studies have shown an increased risk of major adverse cardiovascular events (MACE) with use of testosterone replacement therapy. Patients should be informed of this possible risk when deciding to use or to continue to use AVEED®.
  • Use in Women - Due to lack of controlled evaluations in women and potential virilizing effects, AVEED® is not indicated for use in women.
  • Potential for Adverse Effects on Spermatogenesis - With large doses of exogenous androgens, including AVEED®, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count.
  • Hepatic Adverse Effects - Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. AVEED® is not known to produce these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue AVEED® while the cause is evaluated.
  • Edema - Androgens, including AVEED®, may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
  • Gynecomastia - Gynecomastia occasionally develops and occasionally persists in patients being treated for hypogonadism.
  • Sleep Apnea - The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases.
  • Lipids - Changes in serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy.
  • Hypercalcemia - Androgens, including AVEED®, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Regular monitoring of serum calcium concentrations is recommended in these patients.
  • Decreased Thyroxine-binding Globulin - Androgens, including AVEED®, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
  • Laboratory Monitoring - Monitor prostatic specific antigen (PSA), hemoglobin, hematocrit, and lipid concentrations at the start of treatment and periodically thereafter.

ADVERSE REACTIONS

AVEED® was evaluated in an 84-week clinical study using a dose regimen of 750 mg (3 mL) at initiation, at 4 weeks, and every 10 weeks thereafter in 153 hypogonadal men. The most commonly reported adverse reactions (≥2%) were: acne, injection site pain, prostate specific antigen increased, hypogonadism, estradiol increased, fatigue, irritability, hemoglobin increased, insomnia, and mood swings.

In the 84-week clinical trial, 7 patients (4.6%) discontinued treatment because of adverse reactions. Adverse reactions leading to discontinuation included: hematocrit increased, estradiol increased, prostatic specific antigen increased, prostate cancer, mood swings, prostatic dysplasia, acne, and deep vein thrombosis.

  • Postmarketing Experience

    Pulmonary Oil Microembolism (POME) and Anaphylaxis

    Serious pulmonary oil microembolism (POME) reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL) in post-approval use outside the United States.

    In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate in post-approval use outside of the United States.

DRUG INTERACTIONS

  • Insulin - Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.
  • Oral Anticoagulants - Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.
  • Corticosteroids - The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

USE IN SPECIFIC POPULATIONS

  • Geriatric Use - There have not been sufficient numbers of geriatric patients in controlled clinical studies with AVEED® to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There are insufficient long-term safety data in geriatric patients to assess the potential risks of cardiovascular disease and prostate cancer.

DRUG ABUSE

AVEED® contains testosterone undecanoate, a Schedule III controlled substance in the Controlled Substances Act. Anabolic steroids, such as testosterone, are abused. Abuse is often associated with adverse physical and psychological effects.

Please see accompanying full Prescribing Information, including Boxed Warning.

REFERENCES

1.
Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother. 2010;11(12):2095-2106.
2.
AVEED® (Prescribing Information). Malvern, PA: Endo Pharmaceuticals Inc; 2015.

Intended for U.S. Residents Only

Rx Only

AVEED® is a registered trademark of Endo International plc or one of its affiliates.

© 2015 Endo Pharmaceuticals Inc. All Rights Reserved. Malvern, PA 19355

  • Privacy/Legal
  • AV-03221(4)/July 2015
  • www.AveedUSA.com
  • 1-800-462-ENDO (3636)
INDICATIONS AND USAGE

AVEED® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.

INDICATIONS AND USAGE AND IMPORTANT SAFETY INFORMATION about AVEED®
INDICATIONS AND USAGE

AVEED® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.

Limitations of use:
  • Safety and efficacy of AVEED® in men with "age-related hypogonadism" have not been established.
  • Safety and efficacy of AVEED® in males less than 18 years old have not been established.
IMPORTANT SAFETY INFORMATION about AVEED®

WARNING: SERIOUS PULMONARY OIL MICROEMBOLISM (POME) REACTIONS AND ANAPHYLAXIS

  • Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.
  • Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.
  • Because of the risks of serious POME reactions and anaphylaxis, AVEED® is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the AVEED® REMS Program.

CONTRAINDICATIONS

  • Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Women who are or may become pregnant, or who are breastfeeding. Testosterone can cause fetal harm when administered to a pregnant woman. AVEED® may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization.
  • Men with known hypersensitivity to AVEED® or any of its ingredients (testosterone undecanoate, refined castor oil, benzyl benzoate).

WARNINGS AND PRECAUTIONS

  • Serious Pulmonary Oil Microembolism (POME) Reactions and Anaphylaxis

    Serious POME reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL). The majority of these events lasted a few minutes and resolved with supportive measures; however, some lasted up to several hours and some required emergency care and/or hospitalization. To minimize the risk of intravascular injection of AVEED®, care should be taken to inject the preparation deeply into the gluteal muscle, being sure to follow the recommended procedure for intramuscular administration.

    In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate.

    Both serious POME reactions and anaphylaxis can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose. Patients with suspected hypersensitivity reactions to AVEED® should not be re-treated with AVEED®.

    Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions and anaphylaxis.

  • AVEED® Risk Evaluation and Mitigation Strategy (REMS) Program

    AVEED® is available only through a restricted program called the AVEED® REMS Program because of the risk of serious POME and anaphylaxis.

    Notable requirements of the AVEED® REMS Program include the following:

    • Healthcare providers who prescribe AVEED® must be certified with the REMS Program before ordering or dispensing AVEED®.
    • Healthcare settings must be certified with the REMS Program and have healthcare providers who are certified before ordering or dispensing AVEED®. Healthcare settings must have on-site access to equipment and personnel trained to manage serious POME and anaphylaxis.

    Further information is available at www.AveedREMS.com or call 1-855-755-0494.

  • Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer - Patients with BPH treated with androgens are at an increased risk of worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at an increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens.
  • Polycythemia - Increases in hematocrit, reflective of increases in red blood cell mass, may require discontinuation of testosterone. Check hematocrit prior to initiating testosterone treatment. It would be appropriate to re-evaluate the hematocrit 3 to 6 months after starting testosterone treatment, and then annually. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable level. An increase in red blood cell mass may increase the risk of thromboembolic events.
  • Venous thromboembolism (VTE) - There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as AVEED®. Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with AVEED® and initiate appropriate workup and management.
  • Cardiovascular Risk - Some postmarketing studies have shown an increased risk of major adverse cardiovascular events (MACE) with use of testosterone replacement therapy. Patients should be informed of this possible risk when deciding to use or to continue to use AVEED®.
  • Use in Women - Due to lack of controlled evaluations in women and potential virilizing effects, AVEED® is not indicated for use in women.
  • Potential for Adverse Effects on Spermatogenesis - With large doses of exogenous androgens, including AVEED®, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count.
  • Hepatic Adverse Effects - Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. AVEED® is not known to produce these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue AVEED® while the cause is evaluated.
  • Edema - Androgens, including AVEED®, may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
  • Gynecomastia - Gynecomastia occasionally develops and occasionally persists in patients being treated for hypogonadism.
  • Sleep Apnea - The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases.
  • Lipids - Changes in serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy.
  • Hypercalcemia - Androgens, including AVEED®, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Regular monitoring of serum calcium concentrations is recommended in these patients.
  • Decreased Thyroxine-binding Globulin - Androgens, including AVEED®, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
  • Laboratory Monitoring - Monitor prostatic specific antigen (PSA), hemoglobin, hematocrit, and lipid concentrations at the start of treatment and periodically thereafter.

ADVERSE REACTIONS

AVEED® was evaluated in an 84-week clinical study using a dose regimen of 750 mg (3 mL) at initiation, at 4 weeks, and every 10 weeks thereafter in 153 hypogonadal men. The most commonly reported adverse reactions (≥2%) were: acne, injection site pain, prostate specific antigen increased, hypogonadism, estradiol increased, fatigue, irritability, hemoglobin increased, insomnia, and mood swings.

In the 84-week clinical trial, 7 patients (4.6%) discontinued treatment because of adverse reactions. Adverse reactions leading to discontinuation included: hematocrit increased, estradiol increased, prostatic specific antigen increased, prostate cancer, mood swings, prostatic dysplasia, acne, and deep vein thrombosis.

  • Postmarketing Experience

    Pulmonary Oil Microembolism (POME) and Anaphylaxis

    Serious pulmonary oil microembolism (POME) reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL) in post-approval use outside the United States.

    In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate in post-approval use outside of the United States.

DRUG INTERACTIONS

  • Insulin - Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.
  • Oral Anticoagulants - Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.
  • Corticosteroids - The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

USE IN SPECIFIC POPULATIONS

  • Geriatric Use - There have not been sufficient numbers of geriatric patients in controlled clinical studies with AVEED® to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There are insufficient long-term safety data in geriatric patients to assess the potential risks of cardiovascular disease and prostate cancer.

DRUG ABUSE

AVEED® contains testosterone undecanoate, a Schedule III controlled substance in the Controlled Substances Act. Anabolic steroids, such as testosterone, are abused. Abuse is often associated with adverse physical and psychological effects.

Please see accompanying full Prescribing Information, including Boxed Warning.